MarketPulse

checkpoint inhibitors

6 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Molecular Partners Ag

Molecular Partners' MP0317 Shows Promise in Nature Cancer, Sparks CD40 Agonist Competition

Molecular Partners published positive Phase 1 data for MP0317, a CD40 agonist, in Nature Cancer, demonstrating tumor microenvironment remodeling with favorable safety in advanced cancer patients.
MOLNPhase 1 clinical trialimmunotherapy
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Oncolytic Virus Immunotherapy Market Poised to Reach $5B by 2031

Global oncolytic virus immunotherapy market projected to exceed $5 billion by 2031, driven by three approved therapies and 150+ clinical candidates advancing combination approaches.
BMYCELGrMRKRHHBYREPL+1clinical trialscancer treatment
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Acrivon's Dual Drug Combo Shows Promise Against Cancer in Preclinical Trial

Acrivon highlights preclinical data for ACR-368 and ACR-2316 combination therapies at AACR 2026, showing synergies with checkpoint inhibitors and ADCs.
ACRVimmunotherapysynergy
BenzingaBenzinga··Nabaparna Bhattacharya

AIM ImmunoTech Surges 73% on Japanese Patent Victory for Cancer Therapy

AIM ImmunoTech ($AIMT) surged 73.66% after securing Japanese patent approval for Ampligen cancer therapy through 2039, strengthening its immuno-oncology portfolio.
AIMintellectual propertyorphan drug designation
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

CTLA-4 Inhibitor Pipeline Expands With 50+ Candidates in Development Across 40+ Companies

Over 40 companies develop 50+ CTLA-4 inhibitor candidates for cancer immunotherapy. Recent FDA approvals and focus on combination strategies drive pipeline expansion.
BMYCELGrAZNIVBIYAGEN+1FDA approvalclinical trials
GlobeNewswire Inc.GlobeNewswire Inc.··Researchandmarkets.Com

Checkpoint Inhibitor Market Analysis: 50+ Players Drive Immuno-Oncology Innovation Through 2026

Over 50 companies compete in the checkpoint inhibitor market with 60+ drug candidates in development. Major consolidation and innovation drive immuno-oncology growth through 2026.
BMYCELGrKYKOYRNAZclinical trialscompetitive landscape